Mozart Therapeutics, Inc

Mozart Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, WA, focused on developing disease-modifying therapies that aim to restore healthy immune system function in patients suffering from autoimmune diseases. The company specializes in first-in-class CD8 Treg modulators that target the underlying causes of immune surveillance dysregulation to promote durable immune homeostasis across various autoimmune disorders.

Building on pioneering research by Professor Mark Davis, Mozart Therapeutics is advancing a pipeline of novel CD8 Treg modulators designed to mitigate the progressive inflammation and tissue damage caused by pathogenic autoimmune responses. Through their innovative approach to immunotherapy, they are committed to transforming the landscape of treatment for autoimmune conditions.

Generated from the website